Tuesday, October 19 2021

The identity of the mysterious Cambridge-Massachusetts-based biotechnology-based big pharmaceutical company Acceleron has yet to be confirmed, but US media points to Merck / MSD or Bristol Myers Squibb.

Acceleron is focused on the research, development and commercialization of treatments for pulmonary and hematologic diseases with drugs that engage the “TGF-beta superfamily,” involved in the body’s ability to regulate cell growth and repair.

Merger rumors began late last week when it was reported that a major pharmaceutical group was about to accept a $ 180 per share takeover bid that would value Acceleron at $ 11 billion. . This report suggested that BMS – which owns 11.5% of Acceleron’s shares – as the most likely buyer, but later reports in a US newspaper named Merck / MSD as the mysterious buyer.

The company has marketed a drug, Reblozyl (luspatercept-aamt), approved in the US, EU and Canada for the treatment of anemia in certain blood disorders. The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).

Reblozyl sales have been growing since its launch in 2019 – BMS declared $ 240 million in the first half of 2021, with Acceleron claiming its share of $ 48 million.

However, US media reports that the ‘jewel in the crown of Acceleron’ is actually sotatercept, a first-class therapeutic fusion protein that recently produced positive results in the PULSAR Phase 2 clinical trial in patients. with pulmonary arterial hypertension (PAH).

PAH is already a multibillion dollar market – in 2017, Johnson & Johnson paid Swiss drug maker Actelion $ 30 billion, including its PAH drugs, while PAH drugs went Collectively achieved $ 1.7 billion in global sales in the first six months of this year.

Now might be the perfect time to switch to Acceleron, as the company plans several Phase 3 trials to support its long-term vision of establishing sotatercept as the lead therapy for patients with PAH at all stages of the disease.

In pulmonology, Acceleron also has an early stage candidate, ACE-1334, which is slated to move into Phase 1b / Phase 2, focused on interstitial lung disease associated with systemic sclerosis (SSc-ILD) later this year.

The FDA awarded sotatercept the breakthrough designation and the EMA granted it priority status in recognition of its potential to treat the underlying disease process of PAH.


Source link

Previous

ADQ acquires Swiss pharmaceutical company Acino

Next

University of Sunderland celebrates 100 years of pharmacy education - Sunderland Magazine

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also